Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379441 | 0.90 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL679332 | 0.87 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL8239374 | 0.87 | SLC6A9 (0.82) | SLC6A9 | |
| SCHEMBL1820937 | 0.86 | SLC6A9 (0.88) | SLC6A9 | |
| SCHEMBL14686257 | 0.83 | SLC6A9 (0.73) | SLC6A9CYP2C9 | |
| SCHEMBL2897170 | 0.83 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL2901870 | 0.83 | SLC6A9 (0.72) | SLC6A9CYP2C9 | |
| SCHEMBL23815795 | 0.83 | SLC6A9 (1.00) | SLC6A9CYP2C9 | |
| SCHEMBL3548889 | 0.83 | SLC6A9 (1.00) | SLC6A9CYP2C9 | |
| SCHEMBL678963 | 0.83 | SLC6A9 (1.00) | SLC6A9CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269782-A1 | USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE | MERCK, SHARP & DOHME LTD. (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-1797035-B1 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1797035-B1 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| WO-2006039221-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | SLC6A9 31/4885CYP2C9 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.